Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

Journal of Gastroenterology

Volumn 49, Issue 3, 2014, Pages 481-491

  Kaji, Kosuke ^a   Yoshiji, Hitoshi ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Aihara, Yosuke ^a   Douhara, Akitoshi ^a   Moriya, Kei ^a   Kawaratani, Hideto ^a   Shirai, Yusaku ^a   Yoshii, Junichi ^a   Yanase, Koji ^a   Kitade, Mitsuteru ^a   Namisaki, Tadashi ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Collagen; DPP4; Hepatic stellate cells; Liver fibrosis; TGF

Indexed keywords

COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR BB; PROCOLLAGEN; SITAGLIPTIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STELLATE CELL; SWINE; UPREGULATION; ANIMAL; DRUG EFFECTS; FISCHER 344 RAT; GENE EXPRESSION REGULATION; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CELL PROLIFERATION; COLLAGEN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-SIS; PYRAZINES; RATS; RATS, INBRED F344; SWINE; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES;

EID: 84897109133     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0783-4     Document Type: Article

References (51)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18. (Pubitemid 40385459)
2. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis. 2007;27:413-26. (Pubitemid 350071841)
3. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655-69. (Pubitemid 351615417)
4. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38-53.
5. Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G709-15.
6. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745-50. (Pubitemid 32927999)
7. Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026-33. (Pubitemid 46669730)
8. Matono T, Koda M, Tokunaga S, Sugihara T, Ueki M, Murawaki Y. The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. Int J Mol Med. 2010;25:875-82.
9. Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamazaki M, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med. 2010;26:407-13.
10. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:G907-13. (Pubitemid 40563130)
11. Kuo WL, Yu MC, Lee JF, Tsai CN, Chen TC, Chen MF. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J Gastrointest Surg. 2012;16:361-9.
12. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705. (Pubitemid 46048557)
13. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30:1344-50. (Pubitemid 46871136)
14. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297:127-36.
15. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-23. (Pubitemid 32755966)
16. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397-408. (Pubitemid 35239574)
17. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471-8. (Pubitemid 36043598)
18. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-94. (Pubitemid 36775376)
19. Gorrell MD, Wang XM, Park J, Ajami K, Yu DM, Knott H, Seth D, et al. Structure and function in dipeptidyl peptidase IV and related proteins. Adv Exp Med Biol. 2006;575:45-54.
20. Piazza GA, Callanan HM, Mowery J, Hixson DC. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem J. 1989;262:327-34. (Pubitemid 19220964)
21. Brill S, Zvibel I, Halpern Z, Oren R. The role of fetal and adult hepatocyte extracellular matrix in the regulation of tissue-specific gene expression in fetal and adult hepatocytes. Eur J Cell Biol. 2002;81:43-50. (Pubitemid 34157018)
22. Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol. 1997;27:337-45. (Pubitemid 27366215)
23. Perner F, Gyuris T, Rakoczy G, Sarvary E, Gorog D, Szalay F, Kunos I, et al. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J Lab Clin Med. 1999;134:56-67. (Pubitemid 29332171)
24. Lakatos PL, Firneisz G, Rakoczy G, Selmeci L, Szalay F. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis. J Hepatol. 1999;30:740. (Pubitemid 29151921)
25. Firneisz G, Lakatos PL, Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol. 2001;36:877-80. (Pubitemid 32656564)
26. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis. 2002;186:1498-502. (Pubitemid 35286121)
27. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Muller E, Rettig WJ, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768-78. (Pubitemid 29247051)
28. Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver. 2002;22:93-101. (Pubitemid 34591248)
29. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935-45. (Pubitemid 41401132)
30. Bhunchet E, Eishi Y, Wake K. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology. 1996;23:811-7. (Pubitemid 26111996)
31. Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. Methods Mol Med. 2005;117:99-113.
32. Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46:878-87. (Pubitemid 46529034)
33. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005;108:277-92. (Pubitemid 40516992)
34. Koyama T, Gao M, Ueda T, Batra S, Itoh K, Ushiki T, Abe K. Different enzyme activities in coronary capillary endothelial cells. Adv Exp Med Biol. 1997;411:359-64. (Pubitemid 27360271)
35. Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K, Dubois V, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem. 2011;392:189-98.
36. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634-45. (Pubitemid 351599721)
37. Kitlinska J, Lee EW, Li L, Pons J, Estes L, Zukowska Z. Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling. Adv Exp Med Biol. 2003;524:215-22. (Pubitemid 36570829)
38. Lakatos PL, Firneisz G, Borcsiczky D, Zalatnai A, Selmeci L, Szalay F. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur J Clin Invest. 2000;30:793-7.
39. Thielitz A, Vetter RW, Schultze B, Wrenger S, Simeoni L, Ansorge S, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol. 2008;128:855-66. (Pubitemid 351374300)
40. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010;213:429-35.
41. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007;56:284-92.
42. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-84. (Pubitemid 37280136)
43. Tsukada S, Westwick JK, Ikejima K, Sato N, Rippe RA. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem. 2005;280:10055-64. (Pubitemid 40395857)
44. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-9. (Pubitemid 34106377)
45. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307. (Pubitemid 44837778)
46. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54:1631-9.
47. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res;2012:716404.
48. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism improves metabolic, biochemical and histopathological indices of nonalcoholic steatohepatitis (NASH) in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G762-72.
49. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type2 diabetes: interactions with metformin. Diabetes. 2009;58:1604-15.
50. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond). 2011;120:73-80.
51. Shang Q, Liu MK, Saumoy M, Holst JJ, Salen G, Xu G. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. Am J Physiol Gastrointest Liver Physiol. 2012;302:G815-23.